114 related articles for article (PubMed ID: 20710050)
1. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.
Brochot E; Castelain S; Duverlie G; Capron D; Nguyen-Khac E; François C
Antivir Ther; 2010; 15(5):687-95. PubMed ID: 20710050
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin considerations in treatment optimization.
Dusheiko G; Nelson D; Reddy KR
Antivir Ther; 2008; 13 Suppl 1():23-30. PubMed ID: 18432160
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
4. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
[TBL] [Abstract][Full Text] [Related]
6. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
7. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.
De Nicolò A; Boglione L; Ciancio A; Cusato J; Strona S; Cardellino CS; Abdi AM; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G; D'Avolio A
Antiviral Res; 2014 Sep; 109():7-14. PubMed ID: 24956496
[TBL] [Abstract][Full Text] [Related]
8. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
9. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.
Maynard M; Pradat P; Gagnieu MC; Souvignet C; Trepo C
Antivir Ther; 2008; 13(4):607-11. PubMed ID: 18672540
[TBL] [Abstract][Full Text] [Related]
10. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
11. Ribavirin in the treatment of chronic hepatitis C.
Martin P; Jensen DM
J Gastroenterol Hepatol; 2008 Jun; 23(6):844-55. PubMed ID: 18565019
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
13. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
[TBL] [Abstract][Full Text] [Related]
14. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
15. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
16. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
Aghemo A; Rumi MG; Colombo M
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
[TBL] [Abstract][Full Text] [Related]
17. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
18. Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
[No Abstract] [Full Text] [Related]
19. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
20. Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response.
Baiocchi L; De Leonardis F; Delle Monache M; Nosotti L; Conti RL; Lenci I; Carbone M; Di Paolo D; Cucchiarelli S; Angelico M
Antivir Ther; 2010; 15(4):633-9. PubMed ID: 20587856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]